Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: Mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 5, 2012, Pages 623-633

  Richardson, Paul G ^a   Eng, Cathy ^b   Kolesar, Jill ^c   Hideshima, Teru ^a   Anderson, Kenneth C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Akt; biomarker; colorectal cancer; D 21266; KRX 0401; multiple myeloma; perifosine; targeted agent

Indexed keywords

BORTEZOMIB; CAPECITABINE; DEXAMETHASONE; FLUOROURACIL; LENALIDOMIDE; PERIFOSINE; PROTEIN KINASE B; SURVIVIN;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL CULTURE; CANCER SURVIVAL; COLORECTAL CANCER; CYTOTOXICITY; DEHYDRATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; RADIOSENSITIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SOLID TUMOR; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; VOMITING; WALDENSTROEM MACROGLOBULINEMIA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CELL LINE, TUMOR; CLINICAL TRIALS, PHASE II AS TOPIC; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DEXAMETHASONE; DRUG EVALUATION, PRECLINICAL; FLUOROURACIL; HUMANS; MULTIPLE MYELOMA; PHOSPHORYLCHOLINE; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84859948881     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.681376     Document Type: Review

References (47)

1. Hilgard P, Klenner T, Stekar J, Unger C. Alkylphosphocholines: a new class of membrane-active anticancer agents. Cancer Chemother Pharmacol 1993;32:90-5 (Pubitemid 23131925)
2. Kondapaka SB, Singh SS, Dasmahapatra GP, et al. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003;2(11):1093-103
3. Vink SR, Schellens JHM, van Blitterswijk WJ, Verheij M. Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. Invest New Drugs 2005;23:279-86 (Pubitemid 40980350)
4. Fleer EAM, Unger C, Kim D-J, Eibl H. Metabolism of other phospholipids and analogs in neoplastic cells. Lipids 1987;22:856-61 (Pubitemid 18001388)
5. Stekar J, Hilgard P, Klenner T, et al. A second generation of alkylphospholipids with high antineoplastic activity [abstract 1996]. Proc Am Assoc Cancer Res 1993;34:335
6. Gills JJ, Dennis PA. Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep 2009;11:102-10
7. Available from: http://www.cancer.org/ Research/CancerFactsFigures/ ColorectalCancerFactsFigures/colorectalcancer- facts-figures-2011-2013-page [Last accessed 30 December 2011]
8. Available from: http://www.cancer.org/ Cancer/MultipleMyeloma/ DetailedGuide/ multiple-myeloma-references [Last accessed 30 December 2011]
9. Hideshima T, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006;107(10):4053-62 (Pubitemid 43726814)
10. Kim HS, Kim TS, Kwan BR, et al. Evaluation of anticancer drug sensitivity and gene expression patterns of a novel Akt inhibitor, perifosine in gastric cancer (poster). AACR
11. Rahmani M, Reese E, Dai Y, et al. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/ 2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res 2005;65:2422-32 (Pubitemid 40490154)
12. Voboril R, Weberova-Voborilova J. Constitutive NF- kappaB activity in colorectal cancer cells: impact on radiation-induced NF-kappa B activity, radiosensitivity, and apoptosis. Neoplasma 2006;53(6):518-23 (Pubitemid 46133514)
13. Leleu X, Eeckhoute J, Jia X, et al. Targeting NF- kappa B in Waldenstrommacroglobulinemia. Blood 2008;111(10):5068-77
14. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005;5:297-309 (Pubitemid 40488635)
15. Poradosu E, Lemmon M, Keleti D. Perifosine selectively inhibits binding of Akt PH domain to PtdIns(3,4)P2 [abstract 1645]. 98th AACR Annual Meeting; 2007
16. Li F, Sethi G. Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 2010;1805:167-80
17. Lin Y, Bai L, Chen W, et al. The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets 2010;14:45-55
18. Voboril R, Hochwald SN, Li J, et al. Inhibition of NF-kappa B augments sensitivity to 5 fluorouracil/folinic acid in colon cancer. J Surg Res 2004;120:178-88 (Pubitemid 38834184)
19. NCT00398879: a randomized placebo-controlled study of perifosine in combination with single agent chemotherapy for metastatic cancer patients. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2006. Available from: http://clinicaltrials. gov/ct2/show/NCT00398879? term=nct00398879&rank=1 [Last accessed 16 December 2011]
20. Bendell JC, Nemunaitis J, Vukelja ST, et al. Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer. J Clin Oncol 2011;36:1980
21. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002;2:927-37 (Pubitemid 37328894)
22. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004;104:607-18 (Pubitemid 38970551)
23. Hideshima T, Richardson P, Anderson KC. Novel therapeutic approaches for multiple myeloma. Immunol Rev 2003;194:164-76 (Pubitemid 36886435)
24. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003;101:1530-4 (Pubitemid 36182530)
25. Hideshima T, Chauhan D, Hayashi T, et al. Antitumor activity of lysophosphatidic acid acyltransferase (LPAAT)-inhibitors, a novel class of agents, in multiple myeloma. Cancer Res 2003;63:8428-36 (Pubitemid 37549499)
26. Romagnoli M, Trichet V, David C, et al. Significant impact of survivin on myeloma cell growth. Leukemia 2007;21:1070-8 (Pubitemid 46672084)
27. Hideshima T, Catley L, Raje N, et al. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol 2007;138:783-91 (Pubitemid 47313207)
28. Schmidt-Hieber M, Dabrowski R, Weimann A, et al. In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines. Invest New Drugs 2010;published online 16 November 2010; doi:10.1007/s10637-010-9576-2.
29. Crul M, Rosing H, de Klerk GJ, et al. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer 2002;38:1615-21 (Pubitemid 34876501)
30. NCT00398697: Phase 1 Trial of the Combination of Perifosine and Gemcitabine. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2006. Available from: http:// clinicaltrials.gov/ct2/show/ NCT00398697?term=perifosine +102&rank=1 [Last accessed 16 December 2011]
31. NCT00005794: A Phase I Trial of Perifosine on a Loading Dose/ Maintenance Dose Schedule in Patients With Advanced Cancer. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2000. Available from: http://clinicaltrials.gov/ct2/ show/NCT00005794? term=perifosine&spons= NCI&phase= 0&rank=4 [Last accessed 16 December 2011]
32. Van Ummerson L, Binger K, Volkman J, et al. A Phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Can Res 2004;10:7450-6 (Pubitemid 39557506)
33. NCT01048580: a Phase I study of perifosine + capecitabine for patients with advanced colon cancer. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2010. Available from: http://clinicaltrials.gov/ct2/show/ NCT01048580? term=NCT01048580&rank=1 [Last accessed 16 December 2011]
34. Greco FA, Infante J, Burris H, et al. Safety and pharmacokinetic (PK) study of perifosine plus capecitabine (P-CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC). Presented at ASCO; 2010
35. Unger C, Berdel W, Hanauske AR, et al. First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours. Eur J Cancer 2010;46(5):920-5
36. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-64 (Pubitemid 46797944)
37. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-8 (Pubitemid 350106711)
38. NCT01097018: a Phase III randomized study to assess the efficacy and safety of perifosine plus capecitabine versus placebo plus capecitabine in patients with refractory advanced colorectal cancer. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2010. Available from: http://clinicaltrials.gov/ ct2/show/NCT01097018? term=NCT01097018&rank=1 [Last accessed 16 December 2011]
39. NCT00375791: an open-label Phase II study of the safety and efficacy of perifosine alone and in combination with dexamethasone for patients with relapsed or relapsed/refractory multiple myeloma. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2006. Available from: http://clinicaltrials.gov/ ct2/show/NCT00375791? term=NCT00375791&rank=1 [Last accessed 16 December 2011]
40. Richardson PG, Lonial S, Jakubowiak A, et al. Multi-center phase ll study of perifosine (KRX-0401) alone and in combination with dexamethasone (dex) for patients with relapsed or relapsed/refractory multiple myeloma: promising activity as combination therapy with manageable toxicity [abstract 1164]. Blood 2007;110:353
41. NCT00415064: an open-label Phase I study of the safety of perifosine in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2006. Available from: http://clinicaltrials.gov/ ct2/show/NCT00415064? term=NCT00415064&rank=1 [Last accessed 16 December 2011]
42. Jakubowiak A, Richardson PG, Zimmerman T, et al. Final phase I results of perifosine (KRX-0401) in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (MM). Blood 2010;116:abstract 3064
43. NCT00401011: an open-label Phase I/II study of the safety and efficacy of perifosine and bortezomib with or without dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with bortezomib. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2006. Available from: http:// clinicaltrials.gov/ct2/show/ NCT00401011? term=NCT00401011&rank=1 [Last accessed 16 December 2011]
44. Richardson PG, Wolf J, Jakubowiak A, et al. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol 2011;Published online on 11 October 2011; DOI:10.1200/ JCO.2010.33.9788.
45. NCT01002248: a Phase III randomized study to assess the efficacy and safety of perifosine added to the combination of bortezomib and dexamethasone in multiple myeloma patients. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2009. Available from: http://clinicaltrials.gov/ ct2/show/NCT01002248? term=NCT01002248&rank=1 [Last accessed 16 December 2011]
46. NCT00422656: a Phase II study of perifosine in patients with relapsed/ refractory Waldenstrom's macroglobulinemia. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2009. Available from: http:// clinicaltrials.gov/ct2/show/ NCT00422656?term=Dana+Farber+06- 077&rank=1 [Last accessed 16 December 2011]
47. Treon S, Hunter P, Matous R, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res 2007;13:3320-5 (Pubitemid 46944918)